By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Oncaspar > Oncaspar Dosage
Miscellaneous antineoplastics
https://themeditary.com/dosage-information/oncaspar-dosage-3588.html

Oncaspar Dosage

Drug Detail:Oncaspar (Pegaspargase [ peg-ah-spar-jase ])

Generic Name: PEGASPARGASE 750[iU] in 1mL

Dosage Form: injection, solution

Drug Class: Miscellaneous antineoplastics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Recommended Dosage

Patients 21 Years of Age or Younger

The recommended dose of ONCASPAR for patients up to and including 21 years of age is 2,500 International Units/m2 intramuscularly or intravenously no more frequently than every 14 days.

Patients More Than 21 Years of Age

The recommended dose of ONCASPAR for adult patients more than 21 years of age is 2,000 International Units/m2 intramuscularly or intravenously no more frequently than every 14 days.

Recommended Premedication

Premedicate patients with acetaminophen, an H-1 receptor blocker (such as diphenhydramine), and an H-2 receptor blocker (such as famotidine) 30-60 minutes prior to administration of ONCASPAR to decrease the risk and severity of both infusion and hypersensitivity reactions [see Warnings and Precautions (5.1)].

Recommended Monitoring and Dosage Modifications for Adverse Reactions

Monitor patients at least weekly, with bilirubin, transaminases, glucose and clinical examinations until recovery from the cycle of therapy. If an adverse reaction should occur, modify treatment according to Table 1.

Table 1. Dosage Modifications
Adverse Reaction Severity* Action
*
Grade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is life-threatening.
Infusion Reaction/Hypersensitivity Reaction [see Warnings and Precautions (5.1)] Grade 1
  • Reduce the infusion rate by 50%
Grade 2
  • Interrupt the infusion of ONCASPAR
  • Treat the symptoms
  • When symptoms resolve, resume the infusion and reduce the infusion rate by 50%
Grade 3 to 4
  • Discontinue ONCASPAR permanently
Thrombosis [see Warnings and Precautions (5.2)] Uncomplicated deep vein thrombosis
  • Hold ONCASPAR
  • Treat with appropriate antithrombotic therapy
  • Upon resolution of symptoms consider resuming ONCASPAR, while continuing antithrombotic therapy
Severe or life-threatening thrombosis
  • Discontinue ONCASPAR permanently
  • Treat with appropriate antithrombotic therapy
Pancreatitis [see Warnings and Precautions (5.3)] Grades 3 to 4
  • Hold ONCASPAR for elevations in lipase or amylase >3 × ULN until enzyme levels stabilize or are declining
  • Discontinue ONCASPAR permanently if clinical pancreatitis is confirmed
Hemorrhage [see Warnings and Precautions (5.5)] Grade 3 to 4
  • Hold ONCASPAR
  • Evaluate for coagulopathy and consider clotting factor replacement as needed
  • Resume ONCASPAR with the next scheduled dose if bleeding is controlled
Hepatotoxicity [see Warnings and Precautions (5.6)] Total bilirubin more than 3 times to no more than 10 times the ULN
  • Hold ONCASPAR until total bilirubin is ≤1.5 times the ULN
Total bilirubin more than 10 times the ULN
  • Discontinue ONCASPAR and do not make up for missed doses

Preparation and Administration

Administer ONCASPAR in a healthcare setting with appropriate medical support and resuscitation equipment to manage hypersensitivity reactions, should they occur [see Warnings and Precautions (5.1)].

ONCASPAR is a clear and colorless solution. Visually inspect parenteral drug products for particulate matter, cloudiness, or discoloration prior to administration. If any of these are present, discard the vial.

When ONCASPAR is administered intramuscularly:

  • Limit the volume at a single injection site to 2 mL.
  • If the volume to be administered is greater than 2 mL, use multiple injection sites.

When ONCASPAR is administered intravenously:

  • Dilute ONCASPAR with 100 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP, using aseptic technique.
  • After dilution, administer immediately into a running infusion of either 0.9% Sodium Chloride, USP or 5% Dextrose Injection, USP, respectively.
  • Administer over a period of 1-2 hours.
  • Do not infuse other drugs through the same intravenous line during administration of ONCASPAR.
  • The diluted solution should be used immediately. If immediate use is not possible, the diluted solution should be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 48 hours. Protect infusion bags from direct sunlight.

ONCASPAR does not contain a preservative. Use only one dose per vial; discard unused product.

Share this Article
Latest News
Medical News

Aging and longevity: What role might coffee play?

Jun 02, 2025
Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by